Legato Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$606K Buy
+29,450
New +$629K 0.05% 500
2026
Q2
– Sell
-21,159
Closed -$414K – 853
2026
Q1
$414K Sell
21,159
-1,655
-7% -$49.2K 0.04% 567
2025
Q4
$710K Buy
22,814
+13,018
+133% +$357K 0.06% 451
2025
Q3
$211K Buy
+9,796
New +$177K 0.02% 512

Other funds holding VRDN

Legato Capital Management's VRDN Position: Q3 2026 in Review

Legato Capital Management opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 29,450 shares worth $606K. The stake represents 0.05% of the portfolio and ranks #500 among its holdings. This is a return to the name: Legato Capital Management previously reported a position in VRDN as recently as Q1 2026.

Legato Capital Management first reported a position in VRDN in Q3 2025 and has held it in 4 quarters since. The position peaked at $710K in Q4 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Legato Capital Management held 29,450 shares of Viridian Therapeutics worth $606K as of Q3 2026.
  • Viridian Therapeutics was a new Legato Capital Management position in Q3 2026.
  • Viridian Therapeutics made up 0.05% of Legato Capital Management's portfolio in Q3 2026, its #500 holding.
  • Legato Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Legato Capital Management's Viridian Therapeutics position peaked at $710K in Q4 2025.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.